A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-8294 Monotherapy in Advanced Solid Tumors
Merck Sharp & Dohme LLC
67 participants
Jul 23, 2025
INTERVENTIONAL
Conditions
Summary
MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
30 µg via intravenous (IV) infusion
100 µg via intravenous (IV) infusion
300 µg via intravenous (IV) infusion
1 mg via intravenous (IV) infusion
3 mg via intravenous (IV) infusion
10 mg via intravenous (IV) infusion
30 mg via intravenous (IV) infusion
70 mg via intravenous (IV) infusion
IV Infusion
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07030712